MedPath

IRCCS ISTITUTO NAZIONALE TUMORI - FONDAZIONE PASCALE

🇮🇹Italy
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

35

Active:22
Completed:1

Trial Phases

4 Phases

Phase 1:23
Phase 2:9
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials

Phase 1
23 (65.7%)
Phase 2
9 (25.7%)
Not Applicable
1 (2.9%)
phase_1_2
1 (2.9%)
Phase 3
1 (2.9%)

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma

Phase 1
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
Other: Bio-specimen Retention
First Posted Date
2011-08-09
Last Posted Date
2015-08-11
Lead Sponsor
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Target Recruit Count
36
Registration Number
NCT01412307
Locations
🇮🇹

Hematology Oncology and Stem Cell Transplantation Unit , IRCCS Fondazione "G.Pascale", Naples, Italy

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.